Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells

被引:11
作者
De Giovanni, C
Nanni, P
Sacchi, A
Soddu, S
Manni, I
D'Orazi, G
Bulfone-Paus, S
Pohl, T
Landuzzi, L
Nicoletti, G
Frabetti, F
Rossi, I
Lollini, PL
机构
[1] Univ Bologna, Canc Res Inst, Bologna, Italy
[2] Regina Elena Canc Inst, Mol Oncogenesis Lab, Rome, Italy
[3] Univ G DAnnunzio, Dept Oncol & Neurosci, Chieti, Italy
[4] IST Biotechnol Satellite Unit, Bologna, Italy
[5] Inst Immunol, Berlin, Germany
关键词
p53; interleukin; 15; interleukin-15; receptors; gene transduction; human rhabdomyosarcoma;
D O I
10.1038/bjc.1998.721
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We recently reported that rhabdomyosarcoma cell lines express and secrete interleukin 15 (IL-15), a tightly regulated cytokine with IL-2-like activity. To test whether the p53-impaired function that is frequently found in this tumour type could play a role in the IL-15 production, wild-type p53 gene was transduced in the human rhabdomyosarcoma cell line RD (which harbours a mutated p53 gene), and its effect on proliferation and expression of IL-15 was studied. Arrest of proliferation was induced by wild-type p53; increased proportions of G(1)- arrested cells and of apoptotic cells were observed. A marked down-modulation of IL-15 expression, at both the mRNA and protein level, was found in p53-transduced cells. Because a direct effect of IL-15 on normal muscle cells has been reported, the presence of IL-15 membrane receptors was studied by cytofluorometric analysis. Rhabdomyosarcoma cells showed IL-15 membrane receptors, which are downmodulated by wild-type p53 transfected gene. In conclusion, wild-type p53 transduction in human rhabdomyosarcoma cells induces the down-modulation of both IL-15 production and IL-15 receptor expression.
引用
收藏
页码:1541 / 1546
页数:6
相关论文
共 30 条
[1]   Interleukin-15 promotes angiogenesis in vivo [J].
Angiolillo, AL ;
Kanegane, H ;
Sgadari, C ;
Reaman, GH ;
Tosato, G .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 233 (01) :231-237
[2]  
BACCHETTI S, 1993, INT J ONCOL, V3, P781
[3]  
BALL KL, 1996, CURR BIOL, V7, P71
[4]   ONCOGENES AND THE STRATEGY OF GROWTH-FACTORS [J].
BASERGA, R .
CELL, 1994, 79 (06) :927-930
[5]   Further characterisation of the p53 responsive element - Identification of new candidate genes for trans-activation by p53 [J].
Bourdon, JC ;
DeguinChambon, V ;
Lelong, JC ;
Dessen, P ;
May, P ;
Debuire, B ;
May, E .
ONCOGENE, 1997, 14 (01) :85-94
[6]   Interleukin-15 protects from lethal apoptosis in vivo [J].
BulfonePaus, S ;
Ungureanu, D ;
Pohl, T ;
Lindner, G ;
Paus, R ;
Ruckert, R ;
Krause, H ;
Kunzendorf, U .
NATURE MEDICINE, 1997, 3 (10) :1124-1128
[7]   REDUNDANCY OF AUTOCRINE LOOPS IN HUMAN RHABDOMYOSARCOMA CELLS - INDUCTION OF DIFFERENTIATION BY SURAMIN [J].
DEGIOVANNI, C ;
MELANI, C ;
NANNI, P ;
LANDUZZI, L ;
NICOLETTI, G ;
FRABETTI, F ;
GRIFFONI, C ;
COLOMBO, MP ;
LOLLINI, PL .
BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1224-1229
[8]   GERMLINE P53 MUTATIONS ARE FREQUENTLY DETECTED IN YOUNG-CHILDREN WITH RHABDOMYOSARCOMA [J].
DILLER, L ;
SEXSMITH, E ;
GOTTLIEB, A ;
LI, FP ;
MALKIN, D .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (04) :1606-1611
[9]  
ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325
[10]   p53 and translational control [J].
Ewen, ME ;
Miller, SJ .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1242 (03) :181-184